CenterPoint Energy

Largest single resiliency investment in CenterPoint history will build on Greater Houston Resiliency Initiative and help address impacts of wide range of extreme weather and other threats 100% of lines serving the most customers will have automation devices capable of self-healing 130,000 stronger, more storm-resilient poles and braces to be installed or replaced This historic investment will reduce storm-related outages by nearly 1 billion minutes Spreading investments over four years vs. three years will minimize bill impacts and help keep customer bills more affordable HOUSTON , June 13, 2025 /PRNewswire/ -- As part of its commitment to build and operate the most resilient coastal grid in the country, CenterPoint Energy (CenterPoint) announced yesterday that it has reached a settlement agreement with parties to its 2026-2028 Systemwide Resiliency Plan (SRP).» Mehr auf prnewswire.com

WAKEFIELD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Agilitas Energy, a leading developer and operator of renewable energy and energy storage systems, today announced the commissioning of a 9.96 megawatt (MW) / 22.4 megawatt-hour (MWh) battery energy storage system (BESS) in Houston, Texas.» Mehr auf globenewswire.com

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs) - Ascendis to host conference call today at 8:00 am ET COPENHAGEN, Denmark, June 09, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 26 interim analysis results from its ongoing COACH Trial, the first clinical trial to evaluate combination treatment with once-weekly investigational TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. Results demonstrated that TransCon hGH boosted treatment benefits of TransCon CNP, resulting in significant growth and proportionality improvements in children with achondroplasia after 26 weeks of combination treatment, with a safety and tolerability profile consistent with those observed for TransCon hGH and TransCon CNP monotherapies.» Mehr auf globenewswire.com